ClinicalTrials.gg
Not yet recruitingNCT04651088Updated Feb 13, 2026

Comparing Alkalinizing Agents Efficacy on Stone Risk in Patients on a Metabolically Controlled Diet

An Early Phase 1 interventional study of Potassium citrate and Sodium bicarbonate in Kidney Stone, sponsored by University of Texas Southwestern Medical Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-13.

Sponsored by University of Texas Southwestern Medical Center · Early Phase 1, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
15
Allocation
Non-randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 193 studies in Kidney Calculi with a site in United States — 42 open to participants now, 58 under way, none of them phase 3. Kidney Calculi · United States.

Planned enrollment
125th of 165
15 · median 47
Started
2026
with 13 others
Phase 1
8 of 193
5 open now
Primary completion
2026-12
later than 22 of 57 live
Registered
115th of 193
by date

Among the 193 studies in Kidney Calculi with a site in United States, this one is the 125th largest by planned enrollment of the 165 interventional ones that give a count, is one of 14 that started in 2026, is one of 8 in phase 1, reaches primary completion later than 22 of the 57 other live ones, and was the 115th registered.

Kidney Calculi

510 studies on the registry are indexed under Kidney Calculi; 147 are open to participants now.

Browse Kidney Calculi studies →

Open to participants now

42 of the 193 studies in Kidney Calculi with a site in United States are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 88 Kidney Calculi studies recruiting now, 48 (55%) set no upper age limit and 23 (26%) stop at 75 or younger; 6 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 193 studies in Kidney Calculi with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to compare over the counter and alternative prescription urinary alkalinizing agents to slow release potassium citrate in their ability to modify urinary parameters associated with stone formation.

Read the detailed description

Kidney stones are a common medical problem, occurring in almost 10% of people in the United States1. Furthermore, 50% of patients will recur within 10 years2. Metabolic testing is advised in recurrent stone formers, as well as those considered high risk, to assess for a specific abnormality which may prompt intervention to prevent future stone formation. Non-surgical interventions include both dietary counselling, as well as pharmacotherapy.

One of the most commonly prescribed class of pharmacotherapies is alkali therapy which can be used to both increase the urinary pH and raise the urine citrate levels. This is particularly useful as correction of very acidic urinary pH (\<5.5) can counteract uric acid crystallization thereby preventing or even dissolving uric acid stones3. Further, citrate has been shown to be a potent inhibitor of calcium stones by binding to the calcium directly4 and inhibiting crystal nucleation, thereby reducing calcium stone formation5,6.

The most commonly utilized preparation of alkali therapy is potassium citrate which has been shown to prevent stone formation better than sodium citrate7. Unfortunately, some forms of potassium citrate (crystal packets) have become unavailable, and the slow release form of potassium citrate (UroCit-K) now exceeds $15/day in cost8. There have been multiple alternative alkali therapies that have been used in place of potassium citrate, including both medical foods and prescription medications, but with little evidence to support their use. A pilot study in order to quantify the metabolic effects of these agents and compare them to potassium citrate will be performed.

03

Conditions studied

  • Kidney Stone

Browse trials for

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults aged 18 and older.
  • with or without a history of stone disease.

Exclusion criteria

Exclusion Criteria:

  • They are unable to take any of the medications due to health reasons.
  • Participants are pregnant or nursing.
  • Participants are unable to adhere to the metabolic diet.
  • Participants had a prior adverse event from one or more of the medications.
05

Study design

Phase
Early Phase 1
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
15 participants (estimated)

Study arms

  • Placebo comparator
    Metabolic diet

    Controlled metabolic diet arm.

    Drug: Potassium citrate · Drug: Sodium bicarbonate · Dietary Supplement: Litholyte · Dietary Supplement: Crystal Lite · Drug: Potassium Bicarbonate

  • Active comparator
    Potassium citrate

    Drug: Potassium citrate · Drug: Sodium bicarbonate · Dietary Supplement: Litholyte · Dietary Supplement: Crystal Lite · Drug: Potassium Bicarbonate

  • Active comparator
    Sodium Bicarbonate

    Drug: Potassium citrate · Drug: Sodium bicarbonate · Dietary Supplement: Litholyte · Dietary Supplement: Crystal Lite · Drug: Potassium Bicarbonate

  • Active comparator
    Litholyte arm

    Drug: Potassium citrate · Drug: Sodium bicarbonate · Dietary Supplement: Litholyte · Dietary Supplement: Crystal Lite · Drug: Potassium Bicarbonate

  • Active comparator
    Crystal Lite

    Drug: Potassium citrate · Drug: Sodium bicarbonate · Dietary Supplement: Litholyte · Dietary Supplement: Crystal Lite · Drug: Potassium Bicarbonate

  • Active comparator
    Potassium Bicarbonate

    Drug: Potassium citrate · Drug: Sodium bicarbonate · Dietary Supplement: Litholyte · Dietary Supplement: Crystal Lite · Drug: Potassium Bicarbonate

Interventions

  • Slow release potassium citrate UroCit-K. Participants will take 20mEq twice daily.

  • 650mg tabs. Take 3 tabs twice daily.

  • Dietary supplementLitholyte

    One packet is taken with 170ml of water. Two packets daily.

  • Dietary supplementCrystal Lite

    The classic lemonade contains 21.7mEq/liter of alkali Therefore, patients will take 2 litres daily to have the 40mEq of alkali daily needed.

  • 20 mEq tablets, one tablet twice daily

06

What researchers measure

Primary outcomes

  1. 24 hour urine volume

    Total urine volume

    Time frame: Change from baseline (Day 4) to initial start on treatment (Day 5)

  2. 24 hour urine volume

    Total urine volume

    Time frame: Change from baseline (Day 4) to end of study (day 12)

  3. 24 hour urine creatinine

    Urine creatinine

    Time frame: Change from baseline (Day 4) to initial start on treatment (Day 5)

  4. 24 hour urine creatinine

    Urine creatinine

    Time frame: Change from baseline (Day 4) to end of study (day 12)

  5. 24 hour urine calcium

    urine calcium

    Time frame: Change from baseline (Day 4) to initial start on treatment (Day 5)

  6. 24 hour urine calcium

    urine calcium

    Time frame: Change from baseline (Day 4) to end of study (day 12)

  7. 24 hour urine potassium

    Urine potassium

    Time frame: Change from baseline (Day 4) to initial start on treatment (Day 5)

  8. 24 hour urine potassium

    Urine potassium

    Time frame: Change from baseline (Day 4) to end of study (day 12)

  9. 24 hour urine sodium

    Urine sodium

    Time frame: Change from baseline (Day 4) to initial start on treatment (Day 5)

  10. 24 hours urine sodium

    Urine sodium

    Time frame: Change from baseline (Day 4) to end of study (day 12)

  11. 24 hours urine citrate

    Urine citrate

    Time frame: Change from baseline (Day 4) to initial start on treatment (Day 5)

  12. 24 hours urine citrate

    Urine citrate

    Time frame: Change from baseline (Day 4) to end of study (day 12)

  13. 24 hours urine uric acid

    Urine uric acid

    Time frame: Change from baseline (Day 4) to initial start on treatment (Day 5)

  14. 24 hours urine uric acid

    Urine Uric Acid

    Time frame: Change from baseline (Day 4) to end of study (day 12)

  15. 24 hours urine oxalate

    Urine oxalate

    Time frame: Change from baseline (Day 4) to initial start on treatment (Day 5)

  16. 24 hours urine oxalate

    Urine oxalate

    Time frame: Change from baseline (Day 4) to end of study (day 12)

  17. 24 hours urine magnesium

    Urine magnesium

    Time frame: Change from baseline (Day 4) to initial start on treatment (Day 5)

  18. 24 hours urine magnesium

    Urine magnesium

    Time frame: Change from baseline (Day 4) to end of study (day 12)

  19. 24 hours urine ammonia

    Urine ammonia

    Time frame: Change from baseline (Day 4) to initial start on treatment (Day 5)

  20. 24 hours urine ammonia

    Urine ammonia

    Time frame: Change from baseline (Day 4) to end of study (day 12)

  21. 24 Hour Urine pH

    Overal Urine pH from 24h urine sample.

    Time frame: Change from baseline (Day 4) to initial start on treatment (Day 5)

  22. 24 Hour Urine pH

    Overal Urine pH from 24h urine sample.

    Time frame: Change from baseline (Day 4) to end of study (day 12)

  23. 24 hour urine phosphorus

    Urine phosphorus

    Time frame: Change from baseline (Day 4) to initial start on treatment (Day 5)

  24. 24 hour urine phosphorus

    Urine phosphorus

    Time frame: Change from baseline (Day 4) to end of study (day 12)

  25. 24 hour urine sulfate

    Urine sulfate

    Time frame: Change from baseline (Day 4) to initial start on treatment (Day 5)

  26. 24 hour urine sulfate

    Urine sulfate

    Time frame: Change from baseline (Day 4) to end of study (day 12)

Secondary outcomes

  1. # of patient who adherence to 100% Medication

    Patient's adherence to medication for duration of study.

    Time frame: At the end of study approximately 10 weeks after start of study.

  2. Total out of pocket cost

    Calculate and compare treatment costs for the different interventions (in American dollars).

    Time frame: At the end of study approximately 10 weeks after start of study.

  3. Patient's Satisfaction Survey

    Patient satisfaction survey, adapted from the Treatment Satisfaction Questionnaire for Medication-14. Patients are queried on their satisfaction, with 9 questions for each medication.

    Time frame: At the end of study approximately 10 weeks after start of study.

  4. Patient's GI Distress

    Patient's GI distress symptom scale measures patients GI distress. There are 18 questions with descriptive answers ranging from "none", "mild", "moderate", "quite a lot" and "unbearable". There are no numerical scores, rather just descriptive scores. "None" means no GI distress, "unbearable" means that you are in a lot of distress from your GI symptoms.

    Time frame: At the end of study approximately 10 weeks after start of study.

07

Study locations

1 site
08

References and documents

Publications

  • Scales CD Jr, Smith AC, Hanley JM, Saigal CS; Urologic Diseases in America Project. Prevalence of kidney stones in the United States. Eur Urol. 2012 Jul;62(1):160-5. doi: 10.1016/j.eururo.2012.03.052. Epub 2012 Mar 31. PubMed 22498635 ↗
  • Uribarri J, Oh MS, Carroll HJ. The first kidney stone. Ann Intern Med. 1989 Dec 15;111(12):1006-9. doi: 10.7326/0003-4819-111-12-1006. PubMed 2688503 ↗
  • Pearle MS, Goldfarb DS, Assimos DG, Curhan G, Denu-Ciocca CJ, Matlaga BR, Monga M, Penniston KL, Preminger GM, Turk TM, White JR; American Urological Assocation. Medical management of kidney stones: AUA guideline. J Urol. 2014 Aug;192(2):316-24. doi: 10.1016/j.juro.2014.05.006. Epub 2014 May 20. PubMed 24857648 ↗
  • Pak CY, Sakhaee K, Fuller C. Successful management of uric acid nephrolithiasis with potassium citrate. Kidney Int. 1986 Sep;30(3):422-8. doi: 10.1038/ki.1986.201. PubMed 3784284 ↗
  • Ryall RL. Urinary inhibitors of calcium oxalate crystallization and their potential role in stone formation. World J Urol. 1997;15(3):155-64. doi: 10.1007/BF02201852. No abstract available. PubMed 9228722 ↗
  • Preminger GM, Sakhaee K, Skurla C, Pak CY. Prevention of recurrent calcium stone formation with potassium citrate therapy in patients with distal renal tubular acidosis. J Urol. 1985 Jul;134(1):20-3. doi: 10.1016/s0022-5347(17)46963-1. PubMed 4009822 ↗
  • Ettinger B, Pak CY, Citron JT, Thomas C, Adams-Huet B, Vangessel A. Potassium-magnesium citrate is an effective prophylaxis against recurrent calcium oxalate nephrolithiasis. J Urol. 1997 Dec;158(6):2069-73. doi: 10.1016/s0022-5347(01)68155-2. PubMed 9366314 ↗
  • Preminger GM, Sakhaee K, Pak CY. Alkali action on the urinary crystallization of calcium salts: contrasting responses to sodium citrate and potassium citrate. J Urol. 1988 Feb;139(2):240-2. doi: 10.1016/s0022-5347(17)42374-3. PubMed 3339718 ↗
  • Stern KL, Canvasser N, Borofsky M, Gleason VM, Kamphuis G, El Tayeb MM, Hsi R, Scotland KB. Alkalinizing Agents: A Review of Prescription, Over-the-Counter, and Medical Food Supplements. J Endourol. 2020 Jan;34(1):1-6. doi: 10.1089/end.2019.0292. Epub 2019 Sep 25. PubMed 31333065 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jul 2026; primary completion for Dec 2026, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2020
First posted
Dec 3, 2020
StartEst.
Jul 1, 2026
Primary completionEst.
Dec 2026
CompletionEst.
Jul 2027
Last update
Feb 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04651088
Responsible party
Brett Johnson (Associate Professor of Urology, University of Texas Southwestern Medical Center) — Principal investigator
First posted
Dec 3, 2020
Start date
Jul 1, 2026 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Jul 2027 (estimated)
Last update
Feb 13, 2026

Study contacts

Brett A Johnson, MD
Contact
brett.johnson@utsouthwestern.edu
214-648-6853
Ashley Gonzalez, MD
Contact
ashley.gonzalez2@utsouthwestern.edu

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Potassium Citrate · Sodium Bicarbonate · Potassium bicarbonate

Start the discussion